Psychiatric pharmacist's role in overcoming barriers to clozapine use and improving management
- PMID: 30842912
- PMCID: PMC6398355
- DOI: 10.9740/mhc.2019.03.064
Psychiatric pharmacist's role in overcoming barriers to clozapine use and improving management
Abstract
Clozapine is an antipsychotic that exhibits superior efficacy and effectiveness for those with schizophrenia and other serious mental illness. However, its side-effect profile and administrative burdens present challenges to its use. In the United States, the medication is grossly underused even though it may improve outcomes and reduce costs. Current barriers to use include lack of prescriber knowledge and confidence, negative prescriber attitudes, special monitoring requirements, administrative factors, lack of clozapine on formularies, lack of support and infrastructure to use the medication within many health systems, and inadequate understanding or acknowledgement of clozapine prescribing and risks by policy makers and payers. Approaches using interprofessional models of care, which include pharmacists specializing in psychiatric care, can help meet the needs of patients receiving clozapine. This article lays out the big picture of barriers to clozapine and how psychiatric pharmacists could play a role in improving access.
Keywords: barriers; clozapine; pharmacists.
Conflict of interest statement
Disclosures: D.L.K. is on the advisory board for Lundbeck and a consultant for HLS Therapeutics. R.C.L. received a speaking fee for the Nevada Psychiatric Association and received an honorarium for the American Pharmacists Association Advisory Board on Pharmacist Administration of Medication from the National Alliance of State Pharmacy Associations for developing a white paper on medication administration by pharmacists.
Similar articles
-
Development of point-of-care testing devices to improve clozapine prescribing habits and patient outcomes.Neuropsychiatr Dis Treat. 2019 Aug 20;15:2365-2370. doi: 10.2147/NDT.S216803. eCollection 2019. Neuropsychiatr Dis Treat. 2019. PMID: 31692521 Free PMC article.
-
Addressing Barriers to Clozapine Underutilization: A National Effort.Psychiatr Serv. 2018 Feb 1;69(2):224-227. doi: 10.1176/appi.ps.201700162. Epub 2017 Oct 16. Psychiatr Serv. 2018. PMID: 29032704 Free PMC article.
-
Prescriber and institutional barriers and facilitators of clozapine use: A systematic review.Schizophr Res. 2018 Nov;201:10-19. doi: 10.1016/j.schres.2018.05.046. Epub 2018 Jun 4. Schizophr Res. 2018. PMID: 29880453
-
The influence of organisational climate on care of patients with schizophrenia: a qualitative analysis of health care professionals' views.Int J Clin Pharm. 2016 Apr;38(2):344-52. doi: 10.1007/s11096-016-0247-z. Epub 2016 Jan 21. Int J Clin Pharm. 2016. PMID: 26797771 Free PMC article.
-
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update.J Clin Psychiatry. 2007 Nov;68(11):1751-62. doi: 10.4088/jcp.v68n1115. J Clin Psychiatry. 2007. PMID: 18052569
Cited by
-
A Comparison of Attitudes, Comfort, and Knowledge of Clozapine Among Two Diverse Samples of US Psychiatrists.Community Ment Health J. 2022 Apr;58(3):517-525. doi: 10.1007/s10597-021-00847-0. Epub 2021 May 29. Community Ment Health J. 2022. PMID: 34052963 Free PMC article.
-
Clozapine prescribing barriers in the management of treatment-resistant schizophrenia: A systematic review.Medicine (Baltimore). 2021 Nov 12;100(45):e27694. doi: 10.1097/MD.0000000000027694. Medicine (Baltimore). 2021. PMID: 34766570 Free PMC article.
-
Clozapine-induced eosinophilia: A case report.SAGE Open Med Case Rep. 2023 Aug 31;11:2050313X231195961. doi: 10.1177/2050313X231195961. eCollection 2023. SAGE Open Med Case Rep. 2023. PMID: 37667744 Free PMC article.
-
Effectiveness of a pharmacist-led tele-psychiatric clinic in managing drug-related problems.J Pharm Policy Pract. 2025 Feb 7;18(1):2460038. doi: 10.1080/20523211.2025.2460038. eCollection 2025. J Pharm Policy Pract. 2025. PMID: 39931673 Free PMC article.
References
-
- Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJM, Birnbaum ML, et al. Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017;174(3):216–29. doi: 10.1176/appi.ajp.2016.16050503. 27919182 DOI: 10.1176/appi.ajp.2016.16050503 PubMed PMID: PubMed PMID: 27919182. - DOI - PMC - PubMed
-
- Warnez S, Alessi-Severini S. Clozapine: a review of clinical practice guidelines and prescribing trends. BMC Psychiatry. 2014;14:102. doi: 10.1186/1471-244X-14-102. 24708834 PMC3999500 DOI: 10.1186/1471-244X-14-102 PubMed PMID: 24708834 PubMed Central PMCID: PubMed PMID: 24708834 PubMed Central PMCID: PMC3999500. - DOI - PMC - PubMed
-
- Wahlbeck K, Cheine M, Essali A, Adams C. Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry. 1999;156(7):990–9. doi: 10.1176/ajp.156.7.990. 10401441 DOI: 10.1176/ajp.156.7.990 PubMed PMID: PubMed PMID: 10401441. - DOI - PubMed
-
- Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry. 2001;158(4):518–26. doi: 10.1176/appi.ajp.158.4.518. 11282684 DOI: 10.1176/appi.ajp.158.4.518 PubMed PMID: PubMed PMID: 11282684. - DOI - PubMed
LinkOut - more resources
Full Text Sources